NASDAQ:DEPO - Depomed Stock Price, News, & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$7.30Today's Range$7.09 - $7.4252-Week Range$4.31 - $9.48Volume940,193 shsAverage Volume1.30 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California. Receive DEPO News and Ratings via Email Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:DEPO Previous Symbol CUSIP24990810 CIK1005201 Webhttp://www.depomedinc.com/ Phone510-744-8000Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable Depomed (NASDAQ:DEPO) Frequently Asked Questions What is Depomed's stock symbol? Depomed trades on the NASDAQ under the ticker symbol "DEPO." How were Depomed's earnings last quarter? Depomed Inc (NASDAQ:DEPO) released its quarterly earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.03. The specialty pharmaceutical company had revenue of $63.27 million for the quarter, compared to analysts' expectations of $63.72 million. The firm's revenue for the quarter was down 37.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.08 earnings per share. View Depomed's Earnings History. What price target have analysts set for DEPO? 2 equities research analysts have issued twelve-month price targets for Depomed's shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Depomed's share price to reach $9.00 in the next year. View Analyst Price Targets for Depomed. What is the consensus analysts' recommendation for Depomed? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Depomed in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Depomed. Has Depomed been receiving favorable news coverage? News headlines about DEPO stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Depomed earned a news sentiment score of -1.1 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Depomed's key competitors? Some companies that are related to Depomed include Advanced Accelerator Application (AAAP), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Egalet (EGLT), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM) and Impax Laboratories (IPXL). What other stocks do shareholders of Depomed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Depomed investors own include Companhia de Saneamento Bsc DEDSP (SBS), Vertex Pharmaceuticals (VRTX), Mercadolibre (MELI), Alphabet (GOOG), Horizon Therapeutics (HZNP), Celgene (CELG), Gilead Sciences (GILD), Bausch Health Companies (BHC), Allergan (AGN) and Clovis Oncology (CLVS). Who are Depomed's key executives? Depomed's management team includes the folowing people: Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)Mr. August J. Moretti, CFO & Sr. VP (Age 67)Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54) What is Depomed's official website? The official website for Depomed is http://www.depomedinc.com/. How can I contact Depomed? Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected] MarketBeat Community Rating for Depomed (NASDAQ DEPO)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 462 (Vote Outperform)Underperform Votes: 376 (Vote Underperform)Total Votes: 838MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Economic Reports Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.